RT Journal Article
SR Electronic
T1 Predicting the severity of disease progression in COVID-19 at the individual and population level: A mathematical model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.01.21254804
DO 10.1101/2021.04.01.21254804
A1 Narendra Chirmule
A1 Pradip Nair
A1 Bela Desai
A1 Ravindra Khare
A1 Vivek Nerurkar
A1 Amitabh Gaur
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.01.21254804.abstract
AB The impact of COVID-19 disease on health and economy has been global, and the magnitude of devastation is unparalleled in modern history. Any potential course of action to manage this complex disease requires the systematic and efficient analysis of data that can delineate the underlying pathogenesis. We have developed a mathematical model of disease progression to predict the clinical outcome, utilizing a set of causal factors known to contribute to COVID-19 pathology such as age, comorbidities, and certain viral and immunological parameters. Viral load and selected indicators of a dysfunctional immune response, such as cytokines IL-6 and IFNα, which contribute to the cytokine storm and fever, parameters of inflammation d-dimer and ferritin, aberrations in lymphocyte number, lymphopenia, and neutralizing antibodies were included for the analysis. The model provides a framework to unravel the multi-factorial complexities of the immune response manifested in SARS-CoV-2 infected individuals. Further, this model can be valuable to predict clinical outcome at an individual level, and to develop strategies for allocating appropriate resources to mitigate severe cases at a population level.Competing Interest StatementNC and RK are employed by SymphonyTech Biologics Inc, and own stock in the company; the opinions of PN do not represent those of Biocon; BD, AG and VN do not have any conflict of interest.Funding StatementThe work with self-fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No clinical samples were used for this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in the paper will be available.